Unicycive Therapeutics Stock Performance
| UNCY Stock | USD 0.64 0.04 5.88% |
The entity has a beta of 0.93, which indicates possible diversification benefits within a given portfolio. Unicycive Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Unicycive Therapeutics is expected to follow. At this point, Unicycive Therapeutics has a negative expected return of -0.25%. Please make sure to validate Unicycive Therapeutics' information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if Unicycive Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Unicycive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate Dose Escalation Data in Clinical and Translational Science | 01/07/2025 |
2 | Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate ... | 01/28/2025 |
3 | Unicycive Therapeutics Buy Rating Reaffirmed at HC Wainwright - MarketBeat | 01/29/2025 |
4 | Unicycive Therapeutics, Inc. Short Interest Update - MarketBeat | 02/14/2025 |
5 | Disposition of 686 shares by Aggarwal Gaurav of Unicycive Therapeutics at 0.49 subject to Rule 16b-3 | 02/18/2025 |
6 | Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between ... | 02/20/2025 |
7 | Acquisition by Pramod Gupta of 41845 shares of Unicycive Therapeutics at 0.49 subject to Rule 16b-3 | 02/26/2025 |
8 | Acquisition by Jermasek Douglas of 115275 shares of Unicycive Therapeutics at 0.74 subject to Rule 16b-3 | 03/04/2025 |
9 | Unicycive Therapeutics, Inc. Short Interest Update | 03/14/2025 |
| Begin Period Cash Flow | 455 K |
Unicycive |
Unicycive Therapeutics Relative Risk vs. Return Landscape
If you would invest 79.00 in Unicycive Therapeutics on December 25, 2024 and sell it today you would lose (15.00) from holding Unicycive Therapeutics or give up 18.99% of portfolio value over 90 days. Unicycive Therapeutics is currently does not generate positive expected returns and assumes 4.5853% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Unicycive, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Unicycive Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Unicycive Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Unicycive Therapeutics, and traders can use it to determine the average amount a Unicycive Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0551
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | UNCY |
Estimated Market Risk
| 4.59 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Unicycive Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Unicycive Therapeutics by adding Unicycive Therapeutics to a well-diversified portfolio.
Unicycive Therapeutics Fundamentals Growth
Unicycive Stock prices reflect investors' perceptions of the future prospects and financial health of Unicycive Therapeutics, and Unicycive Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Unicycive Stock performance.
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 35.21 M | ||||
| Shares Outstanding | 103.8 M | ||||
| Price To Book | 2.40 X | ||||
| Price To Sales | 62.82 X | ||||
| Revenue | 675 K | ||||
| EBITDA | (30.18 M) | ||||
| Net Income | (30.54 M) | ||||
| Cash And Equivalents | 10.57 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 811 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.43 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (18.28 M) | ||||
| Earnings Per Share | (0.46) X | ||||
| Market Capitalization | 66.75 M | ||||
| Total Asset | 14.19 M | ||||
| Retained Earnings | (64.54 M) | ||||
| Working Capital | (4.13 M) | ||||
About Unicycive Therapeutics Performance
Evaluating Unicycive Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Unicycive Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Unicycive Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.94) | (2.03) | |
| Return On Capital Employed | 5.59 | 6.42 | |
| Return On Assets | (1.94) | (2.03) | |
| Return On Equity | 7.22 | 6.75 |
Things to note about Unicycive Therapeutics performance evaluation
Checking the ongoing alerts about Unicycive Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Unicycive Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Unicycive Therapeutics generated a negative expected return over the last 90 days | |
| Unicycive Therapeutics has some characteristics of a very speculative penny stock | |
| Unicycive Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 675 K. Net Loss for the year was (30.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Unicycive Therapeutics currently holds about 10.57 M in cash with (18.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Unicycive Therapeutics, Inc. Short Interest Update |
- Analyzing Unicycive Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Unicycive Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Unicycive Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Unicycive Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Unicycive Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Unicycive Therapeutics' stock. These opinions can provide insight into Unicycive Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.